Novel heterozygous variants in KMT2D associated with holoprosencephaly.
Cedrik Tekendo-NgongangPaul S KruszkaAriel F MartinezMaximilian MuenkePublished in: Clinical genetics (2019)
Lysine methyltransferase 2D (KMT2D; OMIM 602113) encodes a histone methyltransferase involved in transcriptional regulation of the beta-globin and estrogen receptor as part of a large protein complex known as activating signal cointegrator-2-containing complex (ASCOM). Heterozygous germline mutations in the KMT2D gene are known to cause Kabuki syndrome (OMIM 147920), a developmental multisystem disorder. Neither holoprosencephaly nor other defects in human forebrain development have been previously associated with Kabuki syndrome. Here we report two patients diagnosed with alobar holoprosencephaly in their antenatal period with de novo monoallelic KMT2D variants identified by trio-based exome sequencing. The first patient was found to have a stop-gain variant c.12565G>T (p.Gly4189*), while the second patient had a missense variant c.5A>G (p.Asp2Gly). Phenotyping of each patient did not reveal any age-related feature of Kabuki syndrome. These two cases represent the first report on association between KMT2D and holoprosencephaly.
Keyphrases
- case report
- copy number
- estrogen receptor
- end stage renal disease
- early onset
- genome wide
- endothelial cells
- ejection fraction
- pregnant women
- newly diagnosed
- machine learning
- signaling pathway
- dna methylation
- gene expression
- deep learning
- amino acid
- prognostic factors
- high throughput
- peritoneal dialysis
- intellectual disability
- dna repair
- neural network